FDA approves Boston Scientific’s FARAPULSE PFA System for pulmonary vein and posterior wall ablation in persistent atrial fibrillation patients.

The new FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software will combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation.

INGEVITY™+ Pacing Leads to include Conduction System Pacing of the Left Bundle Branch Area.

The ACURATE Prime valve system is designed with several features to build upon the clinical performance of the ACURATE neo2 platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

The new indication for NSBP expands the use of the WaveWriter SCS Systems to patients who have had limited options for treating their lower back pain.

Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system.

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB.

Nearly 50% of American adults living with diabetes will be affected by diabetic neuropathy complications in their lifetime.

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety.

The first-of-its-kind, expandable cryoballoon catheter advances cryoablation therapy, addressing key limitations with traditional systems.